{"schema":"sb.node.v1","id":"sb:e/7091538943d96e3ad67380ac","kind":"entity","label":{"text":"braf v600e","locale":"en"},"identity":{"anchor":"label:en:braf v600e","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T23:32:17.032179+00:00","snapshot":"deploy ce499e327bbc6c11c122c4b44e4dddd7b7b35d11"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":41,"separatePublishers":16,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-02","to":"2026-10-06","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.146: about 85% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","precision_medicine","pubmed_targeted"],"activeDays":33,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/6b73edeb420631e7d840ef17","kind":"observation","label":"Anticancer Drugs · 2026-09-30 · Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case r…","url":"https://doi.org/10.1097/CAD.0000000000001846"},{"id":"sb:o/e50f170205583c9ffce26409","kind":"observation","label":"Annals of Oncology · 2026-09-13 · A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3","url":"https://www.sciencedirect.com/science/article/pii/S0923753426001791?dgcid=rss_sd_all"},{"id":"sb:o/01857dacc166c0f06f83d15a","kind":"observation","label":"Clinical Colorectal Cancer · 2026-09-11 · Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A …","url":"https://www.sciencedirect.com/science/article/pii/S1533002826000046?dgcid=rss_sd_all"},{"id":"sb:o/3ef642698a6c25e4c929c63f","kind":"observation","label":"J Dermatol · 2026-09-04 · Eruptive Melanocytic Nevi Associated With Encorafenib and Cetuximab Therapy in Two Patients With BRAF V600E-Mutated Colorectal Cancer.","url":"https://doi.org/10.1111/1346-8138.70488"},{"id":"sb:o/25a74a90ffc211df49d8bc71","kind":"observation","label":"crc-digest · 2026-09-03 · Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC","url":"https://www.sciencedirect.com/science/article/pii/S1533002826000678?dgcid=rss_sd_all"},{"id":"sb:o/1bacb96a41f927102c69313c","kind":"observation","label":"Clin Colorectal Cancer · 2026-09-02 · Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer.","url":"https://doi.org/10.1016/j.clcc.2026.08.006"},{"id":"sb:o/bf24aa04b940d94118fd0628","kind":"observation","label":"crc-digest · 2026-08-25 · Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China","url":"https://doi.org/10.3389/fphar.2026.1746058"},{"id":"sb:o/e5e3d315bc5eab60b73661ae","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-06 · High-volume cervical lymph node metastasis in papillary thyroid carcinoma: development and external validation of an interpretable prediction model","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1963925"},{"id":"sb:o/eeec19ee9c3df1296cf7abf3","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-02 · Case Report: Multiple radiotherapy courses for extensive recurrent cutaneous metastases from colorectal cancer","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1910929"},{"id":"sb:o/8aff0a11dac3174daa926982","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-01 · RTK–RAS pathway alterations in hepatocellular carcinoma and cholangiocarcinoma: a multicohort genomic and single-cell transcriptomic study","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1963032"}],"cursor":"c1.eyJpZCI6InNiOmUvNzA5MTUzODk0M2Q5NmUzYWQ2NzM4MGFjIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDIzOjMyOjE3LjAzMjE3OSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":5,"byKind":{"co-mentioned":5},"items":[{"kind":"relation","label":"co-mentioned with braf (41 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/593e374e4f97be70e14a0a5b"},{"kind":"relation","label":"co-mentioned with colorectal cancer (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2577fca8f970ee889f70ed61"},{"kind":"relation","label":"co-mentioned with egfr (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d00581e1565798f492548787"},{"kind":"relation","label":"co-mentioned with immunotherapy (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4723a2c909cc4e27e3982eec"},{"kind":"relation","label":"co-mentioned with kras (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1645c2f62e87847ee6692253"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/7091538943d96e3ad67380ac","mcp":"traverse {\"id\":\"sb:e/7091538943d96e3ad67380ac\"}","page":"/entity/braf-v600e/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7091538943d96e3ad67380ac\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7091538943d96e3ad67380ac\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7091538943d96e3ad67380ac\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7091538943d96e3ad67380ac\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}